Notably, immune checkpoint inhibitors (ICIs), particularly anti‐programmed cell death 1 (PD1) and anti‐programmed cell death ligand 1 (PD‐L1), have shown clinical efficacy in clinical tumour immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.